Onderzoeksgrade Diridavumab

Diridavumab, thealternativenamesCR6261, isahumanmonoclonalantibodydirectagainstinfluenzaAhemagglutinin.TheCR6261antibodywasfirstdiscoveredbytheScrippsInstituteandCrucell, adutchbiopharmaceuticalcompany, andlaterdevelopedbyJanssenPharmaceuticalCompaniesofJohnson&Johnsonunderthetradenamediridavumab. Cr6261isunderinvestigationinclinicaltrialNCT02016066 (AStudytoAssesstheSafety, PharmacokineticsandImmunogenicityofDiridavumabinJapaneseHealthyParticipants) .

CR-6261, CR6261, CAS:1393659-46-5

Mammalian Cells

HA/Hemagglutinin

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Protein A/G purified from cell culture supernatant.

1.41mg/ml

Please contact with the lab for this information.

>95% as determined by SDS-PAGE.

Liquid

0.01M PBS, pH7.4.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at4°C short term (1-2weeks) . Store at-20°C 12 months. Store at -584°C long term.

For research use only. Not suitable for clinical or therapeutic use.

0.01M PBS, pH7.4.

InfluenzaAvirus

IgG1, lambda